Loading patent…
AssigneeThe United States of America, as represented by the Secretary, Dept. of Health and Human Services
InventorsGenyan Yang, Charles Todd Davis
Estimating the term…
Disclosed herein are methods for detecting presence of a target nucleic acid (such as an influenza virus nucleic acid) in a sample. In some embodiments, the methods include contacting the sample with a first probe capable of hybridizing to the target nucleic acid and a second probe capable of hybridizing to the target nucleic acid, contacting the resulting complex with one or more gap filling reagents, thereby producing a gap-filled target nucleic acid, isolating and amplifying the gap-filled target nucleic acid. The amplified gap-filled target nucleic acid covalently linked to the substrate is then detected, for example with a detectably labeled probe. Also disclosed herein are probes capable of hybridizing to influenza virus nucleic acids. The disclosure also includes kits for detecting and/or discriminating influenza virus nucleic acids in a sample. In some examples, the kits include two or more of the disclosed probes.
A method of detecting an influenza virus nucleic acid in a sample, comprising:
(canceled)
(canceled)
10-11. (canceled)
(canceled)
16-20. (canceled)
(canceled)
25-27. (canceled)
A probe for detecting presence of an influenza virus nucleic acid in a sample, wherein:
(canceled)
A probe for detecting presence of an influenza virus nucleic acid in a sample, wherein the probe comprises the nucleic acid sequence of any one of SEQ ID NOs:
33-34. (canceled)
36-37. (canceled)
(canceled)
The kit of claim 37, further comprising:
(canceled)
The kit of claim 37, wherein at least one of the pair of probes is covalently linked to a substrate.
(canceled)
A method of detecting presence of a target nucleic acid in a sample, comprising:
47-50. (canceled)
60-63. (canceled)
65-69. (canceled)
Dependencies are inferred from the claim text.